Cognition Therapeutics Inc — Cash Flow (NASDAQ:CGTX) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities -3.63 M-18.53 M-16.02 M-28.47 M -29.53 M Cash from investing activities -27 K-171 K-147 K-4 000 — Cash from financing activities 53.2 M5.55 M4.52 M23.57 M 47.35 M Free cash flow -3.66 M-18.7 M-16.16 M-28.48 M -29.53 M

Notizie

Cognition Therapeutics incontra la FDA per farmaco contro la demenza a corpi di Lewy

Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug

Il farmaco DLB di Cognition mostra risultati positivi in trial di fase 2

Cognition’s DLB drug shows positive results in phase 2 trial

Cognition Therapeutics completa l’arruolamento nel programma di accesso esteso

Cognition Therapeutics completes enrollment in expanded access program

Cognition Therapeutics delinea i piani di Fase 3 per farmaco contro l’Alzheimer

Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug

Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)

Cognition Therapeutics completa l’arruolamento nella sperimentazione di farmaco per l’Alzheimer

Cognition Therapeutics completes enrollment in Alzheimer’s drug trial

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?